We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

SynCo Bio Partners Completes Manufacture and Release of Actogenix’ Lead Product for Phase II Clinical Trials

News   May 16, 2008

 
SynCo Bio Partners Completes Manufacture and Release of Actogenix’ Lead Product for Phase II Clinical Trials
 
 
 

RELATED ARTICLES

RNA Folding Insights Lead to New Therapeutics and Synthetic Biology Technologies

News

A research team has uncovered a new understanding of how RNA molecules act as cellular "biosensors" to monitor and respond to changes in the environment by controlling gene expression.

READ MORE

British Columbia’s HPV Vaccination Program Reduces Cervical Pre-cancer Rates by > 50%

News

British Columbia’s school-based human papillomavirus (HPV) immunization program is reducing rates of cervical pre-cancer in B.C. women, according to a new study.

READ MORE

Ranitidine Recalled Due to Potential Carcinogen Contamination

News

Teva UK Ltd is recalling unexpired stock of certain batches of two types of Ranitidine medicines – used to treat conditions such as heartburn and stomach ulcers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE